SCM
KNTE

Soleus Capital Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Soleus Capital Management’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-109,000
Closed -$3.4M – 82
2021
Q1 		$3.4M Buy
+109,000
New +$3.8M 0.61% 33

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Soleus Capital Management's KNTE Position: Q2 2021 in Review

Soleus Capital Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2021, closing a stake of 109,000 shares — an estimated $3.4M sold.

Soleus Capital Management first reported a position in KNTE in Q1 2021 and held it in 1 quarter. The position peaked at $3.4M in Q1 2021. 62 funds tracked by Wall St. Rank hold KNTE as of Q2 2021.

  • Soleus Capital Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Soleus Capital Management sold 109,000 Kinnate Biopharma Inc. Common Stock shares in Q2 2021, an estimated $3.4M.
  • Soleus Capital Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Soleus Capital Management's Kinnate Biopharma Inc. Common Stock position peaked at $3.4M in Q1 2021.
  • 62 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2021.

Based on Soleus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.